The Antitrust Lawsuit Over Compounded GLP-1 Access
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
A compounding pharmacy is suing the two biggest makers of GLP-1 medicines, claiming they used exclusive deals with telehealth companies to choke off access to compounded GLP-1 products (Strive complaint). Both companies deny it and have asked the court to throw the case out, so nothing is decided yet (MLex). Its outcome could still shape whether compounded GLP-1s stay an easy option for patients.
Who This Helps
This is for anyone using or considering a compounded GLP-1 product, anyone who found one through a telehealth service, and anyone trying to make sense of the headlines without a law degree. It is also for caregivers who want to know whether a loved one's access is at risk.
Does This Change Your Access Right Now?
No. This is an early-stage lawsuit with no ruling, so the filing by itself does not change what you can get today. What actually governs compounded GLP-1 availability is the FDA's rules on compounding and drug shortages, which is a separate track from this court case (FDA). If your access changes, it is far more likely to come from those rules than from this lawsuit.
What the Lawsuit Claims
The pharmacy, Strive, alleges that the drugmakers signed exclusive agreements with telehealth platforms that barred those platforms from working with compounding pharmacies, which it says kept clinicians from prescribing and patients from getting compounded GLP-1 products (Strive complaint). These are allegations in a complaint, not facts a court has found.
The complaint also claims the companies interfered with compounders' payment processors and social media accounts and described compounded medicines as illegal or unsafe, all to protect sales of their branded medicines like Ozempic, Wegovy, Mounjaro, and Zepbound (STAT).
What Lilly and Novo Say
Both companies asked the court to dismiss the case in April 2026, telling the judge they did not enter exclusive agreements to block competing compounded GLP-1s and that their telehealth contracts only require platforms to follow applicable laws and professional standards (MLex).
Novo Nordisk has called the claims without merit and said it will defend against them in court (Bloomberg Law). A motion to dismiss is a request to end a case early, not a ruling, so the court has not sided with either party.
Why This Matters for Compounded Access
The heart of the dispute is how patients reach compounded GLP-1 products in the first place. Many people found these products through telehealth services, so if those routes narrow, fewer patients may be able to start or stay on a compounded option (Strive complaint). Whether that is happening because of exclusive deals or for other reasons is exactly what the case will test, and the answer is not settled.
How Compounded GLP-1s Fit the Legal Picture
Compounded medicines are made by pharmacies for specific patient needs and are not FDA-approved finished drugs, so they sit in a different legal category than the brands (FDA). That does not make them a grey-market product. Licensed 503A and 503B pharmacies operate within real rules: 503A pharmacies compound on individual prescriptions under state boards, and 503B outsourcing facilities register with the FDA and meet its manufacturing standards.
Access to compounded GLP-1s widened during the national shortage and has tightened as the FDA says supply has stabilized, which is the backdrop the lawsuit is playing out against (FDA). If you want the deeper version, our explainer on how compounding pharmacies are regulated walks through it, and our guide to grey-market peptides covers what falls outside these legal pathways.
What You Can Do While the Case Plays Out
You do not need to make any sudden moves over a lawsuit that has not been decided. A few steady habits protect you no matter how it turns out.
- Confirm your pharmacy is a licensed 503A or 503B facility, and ask where it sources its medicine and who is compounding it (FDA).
- Ask your prescriber about both compounded and FDA-approved options so you understand the trade-offs before you choose.
- Compare telehealth providers and transparent pricing, including HSA and FSA options, with the GLP Winner provider survey, so a change at one provider does not leave you stuck.
What this means for you: treat the lawsuit as a useful context for how the market works, not as a reason to drop a treatment that is working for you. Decisions about your medicine belong with you and your prescriber.
Final Takeaway
A compounding pharmacy and two drug giants are fighting over how patients reach compounded GLP-1 products. Each side tells a very different story, and the court has not picked one yet.
For now, your access today is shaped more by FDA shortage and compounding rules than by this case. That is the place to keep your attention.
If you use a compounded option, the steady move is to know your pharmacy and keep your prescriber in the loop. Those habits hold up no matter what the judge decides.
The case is worth following because it could redraw the paths to compounded medicine. It is not a reason to act in a hurry.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
The difference between 503A and 503B compounding pharmacies, why it matters, and how to stay safe when getting GLP-1 compounded treatments.
Proposed state and federal compounding laws could affect GLP-1 access in 2026. Here’s what’s changing and why it matters.
Lab testing finds many grey-market peptides miss their purity claims, with heavy metals and bacterial contamination in samples. Here is what to know.
Categories
Curated by
